Q2 FY2026 EarningsQ2 FY2026 results significantly exceeded consensus expectations across the top and bottom lines. Total revenue reached $25.1M vs. the $14.9M expected, driven by the rapid commercial adoption of PALSONIFY which generated $24.0M in net product revenue. GAAP EPS was -$1.14, beating the consensus mean of -$1.21. On July 6, 2026, the company entered into a definitive agreement to be acquired by Vertex Pharmaceuticals for approximately $10.0 billion, leading to the withdrawal of all future guidance.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Crinetics Pharmaceuticals(CRNX) the Revenue is 25.12 M (+2336%);the EBIT is -132.46 M (-2.59%);the EPS is -1.14 (+7.14%).
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
0.03B2336.28%
----
----
EBIT
-0.13B2.59%
----
----
EPS
-1.14497.14%
----
----
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf